<DOC>
	<DOCNO>NCT01610414</DOCNO>
	<brief_summary>The purpose study evaluate efficacy GSK Biologicals ' vaccine GSK1437173A prevention Herpes zoster ( HZ ) autologous haematopoietic cell transplant recipients 18 year age old . To end , study evaluate vaccine efficacy ( VE ) GSK1437173A vaccine , administer 2-dose schedule , compare placebo reduce risk develop HZ population .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster Vaccine GSK1437173A</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Study entry ( enrollment ) occur Prevaccination visit . Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . A male female age 18 year old time study entry . Has undergone undergo autologous HCT within 5070 day prior first vaccination study vaccine/placebo , plan additional HCTs . Female subject nonchildbearing potential may enrol study . For study population , nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . OR Female subject childbearing potential may enrol study , subject practice adequate contraception 30 day prior vaccination study vaccine/placebo , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 12 month completion vaccination series ( i.e. , Month 13 ) . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine/placebo , plan use study period . However , investigational use register nonregistered product treat subject 's underlying disease HCT undertaken , complication underlie disease , allow . Previous vaccination HZ varicella within 12 month precede first dose study vaccine/placebo . Planned administration study HZ vaccine study vaccine . Occurrence varicella HZ episode clinical history within 12 month precede first dose study vaccine/placebo . History allergic disease reaction likely exacerbate component vaccine study material equipment . Prophylactic antiviral therapy activity Varicella Zoster Virus ( VZV ) expect last 6 month transplantation . Administration and/or plan administration vaccine foreseen study protocol HCT 30 day last dose study vaccine/placebo . However , license nonreplicating vaccine may administer 8 day prior dose 1and/or 2 , and/or least 14 day dose study vaccine/placebo . HIV infection clinical history . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution ( childbearing potential ) Month 13 ( i.e. , one year last dose study vaccine/placebo ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Observer-blind</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Safety</keyword>
	<keyword>Adult autologous haematopoietic cell transplant recipient</keyword>
	<keyword>Herpes Zoster</keyword>
</DOC>